Evaluation of radiochemical purity of commercially available I-123 MIBG

Objectives I-123 meta-iodobenzylguanidine (MIBG) is increasingly utilized in nuclear medicine, particularly in nuclear cardiology. There are currently two commercially available products; Adreview (GE Healthcare) and I-123 MIBG (Anazao Healthcare). Our facility evaluated the radiochemical purity of these two commercially available radiopharmaceuticals.

Methods The radiochemical purity of Adreview and I-123 MIBG (Anazao) was evaluated at receipt/reconstitution and at 4 hours after receipt using a miniaturized chromatography system consisting of silicic acid chromatography paper (Varian, Inc) with 0.9% sodium chloride. I-123 MIBG was spotted at the origin, developed in saline, cut at Rf = 0.7 and counted using a multichannel analyzer interfaced to a NaI (TI) well detector. For each specific evaluation, three replicate samples were analyzed and the data statistically summarized.

Results The radiochemical purity of Adreview at receipt and at four hours after receipt was 94.5% and 93.5%, respectively. The radiochemical purity of I-123 MIBG (Anazao Healthcare) at reconstitution and four hours later was 92.9% and 91.1%, respectively.

Conclusions The labeling efficiency of Adreview (GE Healthcare) and I-123 MIBG (Anazao Healthcare) was assessed. The radiochemical purity of both products was greater than 90% at 4 hours after receipt/reconstitution.